1005397-64-7

Usage

Uses

Used in Pharmaceutical Industry:
cis-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of drugs for the treatment of various conditions, such as glaucoma and dry mouth. Its role in drug development is crucial due to its ability to improve the stability and bioavailability of the active pharmaceutical ingredients, leading to more effective therapeutic outcomes.
Used in Glaucoma Treatment:
In the field of ophthalmology, cis-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is used as a precursor in the development of medications that lower intraocular pressure, a key factor in managing glaucoma. cis-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester contributes to the creation of drugs that can effectively reduce the risk of vision loss associated with this condition.
Used in Dry Mouth Treatment:
cis-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester is also utilized in the development of pharmaceuticals aimed at treating dry mouth, or xerostomia. cis-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester plays a role in formulating medications that stimulate saliva production, thereby alleviating the symptoms of dry mouth and improving oral health.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 13200-35-6 (2S,6R)-2,6-dimethylpiperidin-4-one 
• 198211-15-3 (2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-one 

Downstream Products

• 146337-39-5 tert-butyl (2S,6R)-4-hydroxy-2,6-dimethyl-piperidine-1-carboxylate 

Relevant academic research and scientific papers

AMINOPYRIMIDINES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula( I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula ( I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Novel kinase inhibitors

The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.